Specialties

It is unclear whether SGLT2i show reduction in mortality in all patients with type 2 or just in patients with type 2 diabetes with increased cardiovascular risk.

This is not one patient’s disaster averted but what I have experienced working in the field of diabetes and obesity for years. Many times patients who are taking glucose lowering and/or anti obesity medications will report different GI complaints-such as bloating, diarrhea, constipation, nausea, vomiting, and GERD. They tell me they are going to see a gastroenterologist for an evaluation.

Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.

Researchers complete examination of class of type 2 medication.

Very low incidence of end stage renal disease (ESRD) was found in patients with childhood-onset diabetes type 1 in Norway.

Study finds disease duration in middle age to be independently related to development of subclinical atherosclerosis and cardiac dysfunction later in life.

An attempt to improve diet quality in youth with type 1 yields less than promising results.

When added to statin therapy in patients with diabetes, ezetimibe provides greater cardiovascular protection than what is seen in individuals without diabetes.

Long-term impact of intrauterine exposure to medication on the offspring remains unclear.

A predictive detection system helps to reduce risk of low blood glucose.